What Are Peptides? A Plain-English Guide to the Science

Three takeaways

1. “Peptide” describes a structure — a short chain of amino acids. It tells you nothing on its own about what a product is for, how it works or whether it is approved.
2. Your body runs on peptide signals such as insulin and the gut hormone GLP-1. A few peptides are approved medicines with tested labels; some sit in cosmetics; many sold online are investigational compounds with no approved use at all.
3. The route (tablet, capsule, spray, cream, injection) and the formulation are part of the claim — and a demonstrated mechanism in cells or mice is not a measured benefit in people.

Evidence and status panel

Table of contents

1. [First, the chemistry: what the word actually means](#first-the-chemistry-what-the-word-actually-means)
2. [Your body already runs on peptide signals](#your-body-already-runs-on-peptide-signals)
3. [Peptide products move in three very different worlds](#peptide-products-move-in-three-very-different-worlds)
4. [Why route and formulation are part of the science](#why-route-and-formulation-are-part-of-the-science)
5. [Mechanism is not a measured benefit](#mechanism-is-not-a-measured-benefit)
6. [How to find your way around this site](#how-to-find-your-way-around-this-site)

First, the chemistry: what the word actually means

Start with the smallest honest definition. Your body builds proteins from twenty-odd building blocks called amino acids. When amino acids link together into a chain — each link formed when the acid end of one amino acid joins the nitrogen end of the next, releasing a molecule of water — chemists call the joint a peptide bond and the resulting chain a peptide. That is the formal definition used in chemistry references: peptides are molecules made from two or more amino acids joined by those amide links [1].

Length gives a rough sorting rule. Chains of roughly 2 to 50 amino acids are conventionally called peptides; chains longer than about that are usually called polypeptides or proteins [2]. It is a labelling convention rather than a law of nature, and some substances straddle it. Insulin, for example, is a peptide hormone of 51 amino acids in two chains linked together — often described either way, depending on the book [3].

Sequence is the order of the amino acids — change it and you change the molecule’s behaviour. Shape is how the chain folds; many peptide signals work only when folded correctly.

None of this says what a peptide is for. The word spans insulin dosed in units for diabetes, a constipation capsule, a face-serum ingredient and compounds that no regulator has approved for anyone. “Peptide” names a chemistry, not a category of use — and that single insight is the antidote to most online peptide marketing.

Your body already runs on peptide signals

The second thing to know: peptides are not exotic. You are producing them right now — peptide signals, each with a specific job and usually a specific receptor it fits like a key.

Insulin is a 51-amino-acid peptide hormone, two chains joined by disulfide bonds, released by the pancreas when blood glucose rises, telling muscle and other cells to take up glucose [3]. GLP-1 (glucagon-like peptide-1) is a peptide hormone made by cells in your gut lining after a meal; it helps release insulin in a glucose-dependent way and slows stomach emptying. The body destroys the natural hormone within minutes using the enzyme DPP-4 — a detail that will matter later [4][5]. Alongside them sit dozens of other peptide signals — neuropeptides governing appetite, mood, pain and blood pressure. They are normal human biology, not “biohacking” equipment.

This matters because of where the marketing enters. Nearly every peptide sold enthusiastically online is named after a signal your body makes or that a laboratory has studied. The existence of a natural signal says nothing about whether an extra dose of a synthetic copy is safe, effective or lawful — it only explains why the idea is attractive.

Peptide products move in three very different worlds

So what are people buying, prescribing or rubbing on? Substances called peptides end up in three distinct regulatory economies, and confusing them is the root of most bad advice.

Approved medicines. A handful of peptide-based products have completed rigorous testing and carry regulator-approved labels specifying exact products, exact routes and exact indications — never the molecule in general. Insulin products are approved prescription medicines for diabetes, supplied for subcutaneous injection [6]. Semaglutide exists as an approved medicine in more than one form — a once-daily oral tablet (initially approved in the US as the first oral GLP-1 receptor agonist tablet in 2019) as well as injectable formulations [7]. Linaclotide is a 14-amino-acid peptide approved as an oral capsule for bowel conditions (irritable bowel syndrome with constipation and chronic idiopathic constipation); its label describes it working locally on the lining of the intestine and instructs the capsule be swallowed whole [8]. Desmopressin, a synthetic vasopressin analogue, is approved as a nasal spray for antidiuretic replacement therapy [9]. Notice four different routes before we even mention an injection.

Cosmetic ingredients. Peptides also appear in skincare as cosmetic ingredients — regulated for cleansing, beautifying or altering appearance, not for treating disease. Copper tripeptide-1 (GHK-Cu — the GHK peptide bound to copper) is listed in the European Commission’s CosIng database as a skin-conditioning cosmetic ingredient [10]; US law draws the line explicitly: a product claiming to treat disease is a drug, and “cosmeceutical” has no legal meaning [11]. A cream containing a peptide is not a medicine, and its presence on a label is not proof of a clinical result [10][11]. Where GHK-Cu research actually stands — and where marketing outruns it — is covered step by step in GHK-Cu Explained.

Investigational compounds and “research” products. Everything else lives in a grey zone the public consistently misreads. Some peptides are genuine investigational medicines: retatrutide is in company-run Phase 3 trials as a once-weekly subcutaneous injection, and its developer, Eli Lilly, states plainly that it is investigational, has not been approved by any regulatory agency, and that no one should take anything claiming to be retatrutide outside a Lilly-sponsored clinical trial [12] — status as checked on 13 October 2026 (we follow its trial programme in Retatrutide Explained). Others are simply sold in vials marked “research use only”: compounds such as MOTS-c and KPV are not approved medicines for human use in the US, and the US FDA has stated it lacks human exposure and safety data for compounded versions — with compounded injectable GHK-Cu flagged for potential immunogenicity risk [13]. “Research use only” is a statement a seller prints on a label — not an approval, a safety clearance or a licence for consumer use.

Approvals are also jurisdiction-specific: a status line in the table is a US statement, not a South African one, and local status should be confirmed with SAHPRA rather than assumed [14].

Why route and formulation are part of the science

A peptide’s usefulness depends on where it needs to act, what destroys it along the way, and what form it was engineered into. The route is not packaging — it is part of the medicine.

Native GLP-1 is destroyed within minutes [4][5], which is why approved GLP-1 medicines are re-engineered analogues built to survive. Whether a given peptide works as a swallowed capsule (linaclotide), a tablet engineered to survive the gut (oral semaglutide) [7], a spray (desmopressin) [9] or an injection (insulin) [6] follows from that engineering. Route also changes exposure: the desmopressin label itself notes that its nasal form delivers an antidiuretic effect around one-tenth that of an equivalent injected dose [9] — the same molecule, a different question.

Formulation carries the same weight: serum, capsule and sterile injectable are different products with different purity, sterility and stability requirements — and a vial from an anonymous online seller is by definition an unverified formulation. The FDA has said it lacks human safety data for several compounded peptides, and that gap is US-relevant background [13]. For GHK-Cu, the topical cosmetic context and the injectable one are simply different questions, with different evidence and different obligations — which is why this site treats them separately. So the shorthand “peptides are injectable” is doubly wrong: most approved peptide medicines are not the products being sold online, and injections are only one route among several. When you evaluate any peptide claim, ask: which route, which formulation, made by whom, for which measured purpose?

Mechanism is not a measured benefit

The last foundation stone: knowing how a peptide acts does not establish that people benefit from taking it.

Researchers describe evidence on a ladder. At the bottom sit laboratory findings — a peptide binds a receptor in a dish, changes a biomarker in cells. Above them, animal studies. Then observational human data, which can show associations but not cause and effect. At the top sit controlled human trials and syntheses of studies, and the steps do not predict each other reliably — promising mechanisms die in human testing constantly. Learning to place a claim on that ladder — and to read a study’s design, endpoints and withdrawals — is exactly what we walk through in How to Read a Peptide Study Without Falling for the Hype.

Approved peptide medicines earned their labels the ordinary way: mechanism first, then years of controlled human trials, then a regulator’s scrutiny. Semaglutide mimics a gut hormone whose biology scientists understood for decades — but approvals came from trial data, not from the mechanism [5][7]. By contrast, compounds with fascinating laboratory stories — MOTS-c in cells and mice, KPV in inflammatory models — have not translated into approved human medicines, and regulators note the human-safety data gap directly [13]; we examine what the KPV evidence does and does not support in KPV Explained. A compound mid-way through a real Phase 3 programme — retatrutide, today — sits between those poles: serious trials exist, approval does not yet, and “promising” is the strongest honest word available [12].

So when you meet a peptide claim online, the useful questions are: What kind of evidence? In what species, at what doses, by which route? Was the outcome measured in humans, or a dish? If there is no answer, you have a mechanism story — not a medicine.

How to find your way around this site

The site is organised around that ladder. Start Here gives newcomers the recommended reading order. Four topic hubs collect articles by field — metabolic health (incretin medicines and trial coverage), mitochondrial science, skin and copper peptides, and inflammation research — while the article index lists everything and the glossary unpacks terms like receptor, agonist and endpoint.

Where you go next should be the evidence guide — it explains every evidence label used on this site (laboratory, animal, observational, human trial, synthesis), how confidence is weighed and why we never turn a mechanism into a promise. It is the companion to every article here, and the page we would hand a friend who has just heard a peptide claim they cannot verify.

Two things this site is not: it is not a clinic, and it is not personal medical advice — articles can explain what trials show, but decisions about your health belong with a qualified practitioner. If you spot an error anywhere, we treat correction requests as a priority: submit a correction.

Known limitations

• Jurisdiction. Every approval statement above cites US-regulated products; the same molecule may carry different status elsewhere. South African status was not determined here and must be checked against current SAHPRA sources before any local claim is published [14].
• Currency. Retatrutide and compounded-peptide statements are dated 13 October 2026 and belong to fast-moving areas; this page is scheduled for review and status must be re-checked if regulatory events intervene.
• Conventions. The 2–50-amino-acid peptide/protein boundary is a working convention; some marketed products sit on it and are described inconsistently in the literature [2][3].
• Deliberate omissions. This article names approved examples with official labels but publishes no doses, no procurement information and no personal-use instructions. Absence of a named example (for instance other incretin medicines) means it has its own dedicated article elsewhere on the site, not that it is less relevant.

FAQ

Are all peptides injectable? No. Among approved medicines alone: linaclotide is an oral capsule, semaglutide comes as a daily tablet, desmopressin as a nasal spray; cosmetic peptides are topical creams. Injection is one route among several — and notably, vials injected and bought online are overwhelmingly not approved medicines.

Are all peptides approved medicines? No — by a wide margin. Approved applies only to specific products, routes and indications in specific jurisdictions. Retatrutide is investigational; MOTS-c and KPV are not approved medicines, with the US FDA noting it has no human safety data for compounded versions [12][13]. “Research use only” is not approval.

Are peptides just small proteins? Structurally, roughly yes: peptides are short amino-acid chains, commonly 2 to 50 residues, with longer chains called polypeptides or proteins — an informal boundary, not a scientific law [1][2].

If a peptide’s mechanism is proven, is the benefit proven? No. Mechanism is a laboratory observation; benefit requires measured results in controlled human trials. The evidence guide explains the difference in detail — it is the single most useful next stop after this article (/evidence-guide/).

How can I check whether a peptide is an approved medicine? Look the product up in an official regulator’s database — for US-labelled products, the FDA’s label database (DailyMed) shows the approved product, route and indications; in South Africa, SAHPRA is the relevant authority; and trial registries show trial status — which is not the same as approval [6][9][14].

Sources

1. IUPAC, Compendium of Chemical Terminology (Gold Book), entry “peptides” (P04479), 5th ed., 2025 — https://goldbook.iupac.org/terms/view/P04479 (accessed 13 October 2026)
2. StatPearls, “Biochemistry, Peptide,” NCBI Bookshelf — https://ncbi.nlm.nih.gov/books/NBK562260 (accessed 13 October 2026)
3. Molecular structure of insulin (51 amino acids, two chains) — PubMed 2676073 — https://pubmed.ncbi.nlm.nih.gov/2676073/ (accessed 13 October 2026)
4. “What Is an L-Cell and How Do We Study the Secretory Mechanisms of the L-Cell?” — PMC8218725 — https://ncbi.nlm.nih.gov/pmc/articles/PMC8218725 (accessed 13 October 2026)
5. “Physiology of incretins (GIP and GLP-1)…” — PubMed 18640588 — https://pubmed.ncbi.nlm.nih.gov/18640588 (accessed 13 October 2026)
6. DailyMed official label, HUMULIN R (insulin human injection) — https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9ec3e28a-cea9-4e45-9057-e5bf8e37014c (accessed 13 October 2026)
7. FDA official label, RYBELSUS (semaglutide tablets, oral) — https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213051s018lbl.pdf; first-oral-GLP-1 context: PMC6969659 — https://pmc.ncbi.nlm.nih.gov/articles/PMC6969659/ (accessed 13 October 2026)
8. DailyMed official label, LINZESS (linaclotide capsules, oral) — https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09beda19-56d6-4a56-afdc-9a77b70b2ef3 (accessed 13 October 2026)
9. DailyMed official label, DESMOPRESSIN ACETATE spray — https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1ac423b8-27a6-4cef-4a82-c50bf81b4f49 (accessed 13 October 2026)
10. European Commission CosIng database, COPPER TRIPEPTIDE-1 (skin-conditioning cosmetic ingredient) — https://ec.europa.eu/growth/tools-databases/cosing/details/55687 (accessed 13 October 2026)
11. FDA, “Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?)” — https://www.fda.gov/cosmetics/cosmetics-laws-regulations/it-cosmetic-drug-or-both-or-it-soap (accessed 13 October 2026)
12. Eli Lilly, “What to know about retatrutide” (updated 30 September 2026; investigational; not approved by any regulatory agency) — https://www.lilly.com/news/stories/what-to-know-about-retatrutide (accessed 13 October 2026)
13. FDA, “Substances in Compounding that May Present Significant Safety Risks” (US framework; entries: GHK-Cu for injectable routes, KPV, MOTs-C) — https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks (accessed 13 October 2026)
14. SAHPRA (South African Health Products Regulatory Authority) — https://www.sahpra.org.za/ (entry point; local status to be verified against current SAHPRA publications before any South African legal claim)

Related label conventions for cosmetics claims: Cosmetic Ingredient Review, Safety Assessment of Tripeptide-1, … and Copper Tripeptide-1 as Used in Cosmetics — https://www.cir-safety.org/sites/default/files/tripep062014final.pdf (accessed 13 October 2026)

Spotted an error? Submit a correction — corrections are reviewed, dated and logged.

Related next reads

• How to Read a Peptide Study Without Falling for the Hype — article 02: how evidence earns, loses and never inherits weight
• Retatrutide Explained: The Science Behind the Triple Agonist — article 04: the most-watched investigational triple agonist
• GHK-Cu Explained: Copper Peptides in Skin Research — article 10: the most-discussed cosmetic peptide, evidence first
• KPV Explained: Inflammation Research and Its Limitations — article 13: what the inflammation evidence does and does not support

Newsletter

The Peptide Science Brief — fortnightly, plainly written research updates and evidence checks, no unapproved-compound promotion, one click to unsubscribe. Subscribe.

Suggest a correction